Nanobody-engineered CAR-T cells directed against membrane-proximal EGFR demonstrated that the hinge domain truncation, while compromising overall cellular functionality, significantly improved tumor-specific selectivity [103]. The gene discussed is EGFR; the disease is neoplasm.